Suppr超能文献

通过抑制不同耐药机制逆转肉瘤180肿瘤细胞对阿霉素的耐药性。

Reversal of doxorubicin-resistance in sarcoma 180 tumor cells by inhibition of different resistance mechanisms.

作者信息

Efferth T, Volm M

机构信息

German Cancer Research Center, Heidelberg.

出版信息

Cancer Lett. 1993 Jul 16;70(3):197-202. doi: 10.1016/0304-3835(93)90231-w.

Abstract

Resistance of tumor cells to doxorubicin is a multifactorial phenomenon. In the present investigation, the ability of resistance modifiers against different resistance mechanisms was analysed. Substances which block P-glycoprotein (P-170) function circumvented resistance of doxorubicin-resistant sarcoma 180 (S180) cells completely (verapamil, thioridazine) or partially (hycanthone), whereas inhibitors of glutathione S-transferase (ethacrynic acid, N-ethylmaleimide, buthionine sulfoximine), and protein kinase C (staurosporine, acridine orange) caused only a partial reversion of resistance. In contrast, an inhibitor of alkaline phosphatase (levamisole) did not overcome doxorubicin-resistance. These results indicate that P-glycoprotein blockers might be more effective to modulate doxorubicin-resistance of S180 cells as compared to other modifiers. Further investigations using other MDR cell lines are required to clarify the generality of these findings.

摘要

肿瘤细胞对阿霉素的耐药性是一种多因素现象。在本研究中,分析了耐药修饰剂针对不同耐药机制的能力。阻断P-糖蛋白(P-170)功能的物质可完全(维拉帕米、硫利达嗪)或部分(海恩酮)克服阿霉素耐药性肉瘤180(S180)细胞的耐药性,而谷胱甘肽S-转移酶抑制剂(依他尼酸、N-乙基马来酰胺、丁硫氨酸亚砜胺)和蛋白激酶C抑制剂(星形孢菌素、吖啶橙)仅能部分逆转耐药性。相比之下,碱性磷酸酶抑制剂(左旋咪唑)不能克服阿霉素耐药性。这些结果表明,与其他修饰剂相比,P-糖蛋白阻滞剂可能更有效地调节S180细胞的阿霉素耐药性。需要使用其他多药耐药细胞系进行进一步研究,以阐明这些发现的普遍性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验